DURECTCorp., a specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, has a line of late-stage development programs including Remoxy®, POSIDUR™, ELADUR®, and TRANSDUR®-Sufentanil. The company’s proprietary oral, transdermal and injectable depot delivery technologies enable new indications and clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information visit the company’s Web site at www.durect.com
Let us hear your thoughts below: